Evaluation of the effectiveness of aprepitant for prevention of nausea and vomiting in patients with breast cancer
https://doi.org/10.21518/2079-701X-2018-19-116-121
Abstract
Chemotherapy regimen AС (doxorubicin and cyclophosphamide) is the most often used in adjuvant chemotherapy of breast cancer. AC regimen is high emetogenic. Objective – to evaluate the effectiveness of the combination of aprepitant, ondansetron and dexamethasone for the prevention of nausea and vomiting in patients with breast cancer receiving chemotherapy regimen AC. Materials and methods:64 female patients with breast cancer received adjuvant chemotherapy regimen AC: doxorubicin 60 mg/m2, cyclophosphamide 600 mg/m2 in day 1, each 21 day 4 cycle. Patients of Group 1 (n=34) received an triple-therapy regimen ( aprepitant 125 mg p.o. in day 1, 80 mg in days 2 and 3, ondansetron 8 mg i.v. in 1 day, dexamethasone 12 mg i.v.in 1 day, then to 8 mg/day p.o. in days 2–4) for prevention of nausea and vomiting. Patients of Group 2 (n = 30) received ondansetron 8 mg i.v. in 1 day, dexamethasone 12 mg i.v.in 1 day, then to 8 mg/day p.o. in days 2-4). The quality of life of patients was assessed by Functional Living Index of emesis (FLIE). Results: During the first cycle of chemotherapy complete control of nausea and vomiting was achieved at 20 (58,8%) patients of Group 1 and at 4 (13.3%) %) patients of Group 2 (p<0.05). The average score on the Functional Living Index of emesis (FLIE) scale in Group 1 was 19.88, in Group 2-38.03 (p<0.05). Conclusion: Adequate regimen for prevention of nausea and vomiting is combination of NK1 receptor antagonist, 5-HT3 receptor antagonist and dexamethasone.
About the Authors
I. A. Koroleva
Medical University «Reaviz», Samara
Russian Federation
Russian Federation
M. V. Kopp
Medical University «Reaviz», Samara
Russian Federation
Russian Federation
A. M. Koroleva
Medical University «Reaviz», Samara
Russian Federation
Russian Federation
References
1. Malignant neoplasms in Russia, 2015 (morbidity and mortality). Under the editorship of Kaprina AD, Starinsky VV, Petrova GV. M.: Hertsen Moscow Oncology Research Center - branch of National Medical Research Radiological Center, Federal State Budgetary Institution of the Ministry of Health of the Russian Federation, 2017: 250.
2. The state of cancer care in Russia, 2017. Under the editorship of Kaprina AD, Starinsky VV, Petrova GV. M.: Hertsen Moscow Oncology Research Center - branch of National Medical Research Radiological Center, Federal State Budgetary Institution of the Ministry of Health of the Russian Federation, 2018: 236.
3. Stenina MB, Zhukova LG, Koroleva IA. et al. Practical guidelines for the drug therapy of invasive breast cancer. Zlokachestvennye Opukholi: Prakticheskie Rekomendacii RUSSCO # 3s2, 2017, 7: 105-134
4. Early Breast Cancer Trialists’ Collaborative Group. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomized trials. Lancet, 2012, 379(9814): 432-444.
5. Bonadonna G, Valagussa P, Moliterni A et al. Adjuvant cyclophos-phamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow up. New Engl. Med., 1995, 332: 901-906.
6. Richardson JL, Marks G, Levine A. The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol, 1988, 5: 1746-1752.
7. Lazslo J. Emesis as limiting toxicity in cancer chemotherapy. In Lazslo J, ed. Antiemetics and cancer chemotherapy. Baltimore, Maryland: Williams & Wilkins, 1983: 1-5.
8. Borison HL, Wang S. Physiology and ph Borison HL, Wang S. Physiology and pharmacology of vomiting. Pharmacol Rev, 1953, 5: 193-230.
9. Cubeddu LX, Pendergrass K, Ryan T et al. Efficacy of oral ondansetron, a selective antagonist of 5HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapy. Am. J. Clin. Oncol., 1994, 17: 137-146.
10. Vladimirova LB, Gladkov OA, Kogonia LM et al. Practical guidelines for the prevention and treatment of nausea and vomiting in cancer patients. Zlokachestvennye Opukholi: Prakticheskie Rekomendacii RUSSCO # 3s2. 2017, 7: 466-476.
11. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J. Clin. Oncol., 2006, 24: 4472-4478.
12. Kris MG, Hesketh PJ, Somerfield MR et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J. Clin. Oncol., 2006, 24(18): 2932-2947.
13. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Ma GJ, Eldridge K, Hipple A et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer, 2003, 97(12): 3090-3098.
14. Hesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin-1antagonist aprepitant for the prevention of chemotherapy-inducednausea and vomiting: A multinational, randomized, double-blind,placebo-controlled trial in patients receiving high-dose cisplatin – The Aprepitant Protocol 052 Study Group. J Clin Oncol., 2003, 21: 4112-4119.
15. Warr DG, Hesketh PJ, Gralla RJ et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J. Clin. Oncol., 2005, 23: 2822-2830.
16. Herrstedt J, Muss HB, Warr DG et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer, 2005 Oct 1, 104(7): 1548-1555.
17. Decker GM, DeMeyer ES, Kisko DL. Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol, 2006, 4: 35-52.
18. Martin AR, Carides AD, Pearson JD, Horgan K, Elmer M, Schmidt C et al. Functional relevance of antiemetic control:experience using the FLIE questionnaire in a randomized study of the NK-1 antagonist aprepitant. Eur J Cancer, 2003, 39: 1395-1401.
19. Aksu G, Dolaşık I, Ensaroğlu F et al. Evaluation of the Efficacy of Aprepitant on the Prevention of Chemotherapy-Induced Nausea and Vomiting and Quality of Life with Functional Living Index Emesis. Balkan Med J, 2013, 30: 64-67.
20. Common Terminology Criteria for Adverse Events, Version 3.0: http://ctep.cancer.gov/protocoldevelopment/electronic_applications / docs/ctcaev3.pdf.
21. Rapoport BL, Jordan K, Boice JA et al. Aprepitant for the prevention of chemotherapyinduced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer, 2010, 18(4): 423-431.
22. Grote T, Hajdenberg J, Cartmell A et al. Combination therapy for chemotherapyinduced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol., 2006, 4: 403-408.
Review
For citations:
Koroleva IA, Kopp MV, Koroleva AM. Evaluation of the effectiveness of aprepitant for prevention of nausea and vomiting in patients with breast cancer. Meditsinskiy sovet = Medical Council. 2018;(19):116-121. (In Russ.) https://doi.org/10.21518/2079-701X-2018-19-116-121
Views:
916
Email this article 